ARIA News Alert Ariad Pharmaceuticals (ARIA) 7.37 12/06/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ariad Pharmaceuticals (ARIA) 7.37 $ARIA

Why Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:36AM CST
ARIA data by YCharts What: Shares of Ariad Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat cancer, surged by 19% in November according to data from S&P Capital IQ after reporting market-topping...
ARIA: 7.37 (+0.17)

Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 20.9% (ARIA)
Comtex SmarTrend(R) - Tue Dec 02, 11:13AM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 20.88% as of today's recent price of $7.15.
ARIA: 7.37 (+0.17)

ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:00AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 7.37 (+0.17)

Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST

HTBX: 4.15 (-0.25), BIB: 131.00 (+2.08), INCY: 75.20 (+1.08), PFE: 31.99 (+0.32), IBB: 308.81 (+2.61), DRGS: 54.01 (+0.01), BIND: 5.74 (-0.40), BMY: 60.65 (+1.76), GSK: 46.04 (+0.15), ONTY: 1.78 (+0.05), ECYT: 6.13 (-0.03), BIS: 45.71 (-0.69), CLVS: 51.05 (+2.42), AZN: 73.72 (-0.22), MRK: 61.49 (+0.57), ARIA: 7.37 (+0.17), IRY: 48.89 (-0.16), IXJ: 103.92 (+0.49), FPRX: 20.81 (+0.16)

Most active Nasdaq-traded stocks
AP - Tue Nov 25, 5:58PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 36.49 (+0.42), GILD: 104.59 (+2.77), FB: 76.36 (+1.12), CMCSK: 56.10 (-0.18), ARIA: 7.37 (+0.17), ARCP: 9.26 (+0.08), MSFT: 48.42 (-0.42), INTC: 37.67 (+0.21), CMCSA: 56.34 (-0.04), AAPL: 115.00 (-0.49), CSCO: 27.50 (-0.27)

Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:25AM CST
Ariad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 48.16 (+0.67), VRX: 144.89 (+0.56), SCMP: 14.06 (+0.49), ARIA: 7.37 (+0.17)

Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison
PR Newswire - Tue Nov 25, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hertz (NYSE:HTZ), Ariad Pharmaceuticals (NASDAQ:ARIA), J C Penney (NYSE:JCP), Sirius XM (NASDAQ:SIRI), Apple (NASDAQ:AAPL), and Sunedison (NYSE:SUNE).
HTZ: 24.22 (-0.03), SUNE: 20.97 (+0.12), JCP: 6.64 (-0.09), ARIA: 7.37 (+0.17), AAPL: 115.00 (-0.49), SIRI: 3.49 (-0.09)

Ariad Pharmaceuticals Rises 9.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Nov 24, 4:56PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.74 to a high of $7.24. Yesterday, the shares gained 9.6%, which took the trading range above the 3-day high of $6.84 on volume of 16.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 7.37 (+0.17)

Iclusig cleared in Australia
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 9:41AM CST

ARIA: 7.37 (+0.17)

ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today
at The Street - Mon Nov 24, 9:04AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 7.37 (+0.17)

Earnings Look Back: Ariad Pharmaceuticals Is Up 14.6% Since Reporting Quarterly Results 2 Weeks Ago (ARIA)
Comtex SmarTrend(R) - Mon Nov 24, 8:34AM CST
19 days ago, on November 5th, 2014, Ariad Pharmaceuticals (NASDAQ:ARIA) reported its earnings. Analysts, on average, expected a loss of $0.29 per share on sales of $16.4 million. Ariad Pharmaceuticals actually reported a loss of $0.27 per share on sales of $14.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.7 million. Since the company's report, shares of Ariad Pharmaceuticals have risen from $5.69 to $6.52, representing a gain of 14.6% in the past 19 days.
ARIA: 7.37 (+0.17)

ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia
Business Wire - Mon Nov 24, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of Iclusig(TM)(ponatinib) in Australia by the Therapeutic Goods Administration (TGA).
ARIA: 7.37 (+0.17)

Ariad Pharmaceuticals Earnings Review: 12 Days after Announcement Shares Up 8.1% (ARIA)
Comtex SmarTrend(R) - Mon Nov 17, 2:37PM CST
A week ago on November 5th, 2014 Ariad Pharmaceuticals (NASDAQ:ARIA) reported earnings and analysts, on average, expected a loss of $0.29 on sales of $16.4 million. The company actually reported a loss of $0.27 per share on sales of $14.7 million, beating EPS estimates by $0.02 and missing revenue estimates by $1.7 million. Since the company's report, shares of Ariad Pharmaceuticals have risen from $5.69 to $6.15, representing a gain of 8.1% in the past 12 days.
ARIA: 7.37 (+0.17)

Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 104.59 (+2.77), IBIO: 0.71 (-0.06), ARIA: 7.37 (+0.17), MNKD: 5.52 (+0.11), CELG: 114.13 (+0.50)

'Mad Money' Lightning Round: A Group to Avoid
at The Street - Fri Nov 14, 5:00AM CST
Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.
DCT: 34.21 (-0.25), CBI: 45.92 (-0.15), FMSA: 7.86 (-0.17), KODK: 22.37 (+1.07), WNR: 40.86 (-1.72), FRT: 132.39 (-0.42), ARIA: 7.37 (+0.17), AFFX: 9.26 (+0.12), ADSK: 60.90 (-0.19)

Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Nov 14, 2:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday November 13. Bullish Calls: Affymetrix (NASDAQ: AFFX ): "This company has over time teased people and then disappointed them, but I believe...
CBI: 45.92 (-0.15), FMSA: 7.86 (-0.17), KODK: 22.37 (+1.07), WNR: 40.86 (-1.72), FRT: 132.39 (-0.42), ARIA: 7.37 (+0.17), ADSK: 60.90 (-0.19), AFFX: 9.26 (+0.12)

Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game
at The Street - Thu Nov 13, 5:49PM CST
Some stocks written off by this market are looking better than ever, Cramer says.
FLEX: 11.29 (+0.02), KMB: 114.04 (-0.56), M: 62.35 (-0.15), WMT: 84.12 (-0.64), FLTX: 35.63 (+1.33), AFFX: 9.26 (+0.12), DPS: 71.94 (-0.18), DCT: 34.21 (-0.25), JACK: 75.65 (-0.22), FMSA: 7.86 (-0.17), CSCO: 27.50 (-0.27), CBI: 45.92 (-0.15), KODK: 22.37 (+1.07), DIS: 93.76 (+0.53), WNR: 40.86 (-1.72), FRT: 132.39 (-0.42), BA: 132.21 (+0.89), PLKI: 54.21 (-0.01), AZO: 587.95 (-0.12), JCP: 6.64 (-0.09), JWN: 75.55 (-0.15), ARIA: 7.37 (+0.17), DOW: 50.16 (+0.39), ADSK: 60.90 (-0.19)

ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting
Business Wire - Thu Nov 06, 8:44AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the schedule of several data presentations on Iclusig(R) (ponatinib) that will take place at the 56th Annual Meeting of the American Society of Hematology (ASH) being held in San Francisco, December 6 to 9, 2014. A total of 17 abstracts were accepted at ASH. The schedule and meeting location for key sessions at ASH, together with the abstract information, are listed below:
ARIA: 7.37 (+0.17)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Everest Group Faces Major Class Action Deadline Looms

Updated Category News Views 166

Everest Group's Headaches Multiply as Deadline Approaches Well, here we find a classic case of Wall Street drama—Everest Group, Ltd. (NYSE:EG), a company whose troubles would make any trader weary. As of late, it's caught up in a nasty class-action lawsuit with stakes high enough to raise eyebrows from Broadway to Bayou. Investors in Everest better be tuned in, because...

Continue Reading
Tenax Therapeutics Faces Legal Heat After Stock Plunge

Updated Category News Views 125

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 121

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading
DraftKings Faces Revenue Cutback; Legal Probe Begins

Updated Category News Views 180

DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...

Continue Reading
Tenax Sued: Investors Face Class Action Over TNX-103

Updated Category News Views 133

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

Continue Reading
Datavault AI's Turbulent Boardroom Saga Escalates

Updated Category News Views 201

The Corporate Chess Game at Datavault AI If there's one thing Wall Street hates, it's uncertainty. And boy, does Datavault AI (NASDAQ: DVLT) deliver plenty of it right now. Founder Nathaniel Bradley has lobbed a lawsuit at the board, claiming that Chairman and CFO Brett Moyer orchestrated a coup to oust him without proper board procedures. Talk about drama fit for a soap...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 151

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Muyuan Foods Spotlights Smart Farming at EuroTier 2026

Updated Category News Views 143

Muyuan Foods Ready to Impress at EuroTier 2026 Let's face it, folks—when you think of game-changers in pig farming, Muyuan Foods Group deserves a nod. They're not just trotting out oinkers left and right; they're steering the whole paddock with innovations in smart pig farming and green development solutions. At EuroTier 2026 in Hanover, Muyuan’s booth—J04 in Hall...

Continue Reading
FuelCell Faces Class Action Crunch as Deadline Looms

Updated Category News Views 122

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 168

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading

Top 5 Most Recently Viewed Articles

Highlights of Week 17: Progress Under Trump’s Leadership

Updated Category News Views 424

Key Achievements in Week 17 Under Trump’s Leadership The recent developments from the Trump Administration have brought significant changes that resonate deeply with many Americans. Week 17 showcased not only triumph but also transformative strategies aimed at improving the lives of citizens. A notable highlight this week was President Trump's Executive Order focused on...

Continue Reading
Philips Shareholder Meeting Yields Positive Leadership Decisions

Updated Category News Views 359

Philips Shareholder Meeting: Key Outcomes from the AGM On a significant day for Royal Philips, shareholders gathered to approve a series of pivotal resolutions during the Annual General Meeting of Shareholders (AGM). The meeting highlighted a robust commitment to enhancing leadership structure and governance, reflecting the company’s dedication to ongoing improvement in...

Continue Reading
Growing Trends in the Lawn and Garden Consumables Market

Updated Category News Views 197

Overview of the Lawn and Garden Consumables Market The Lawn and Garden Consumables market is poised for significant growth, with a future projected value of approximately USD 38 billion by 2034. This sector includes essential products like fertilizers, seeds, pesticides, and more, serving various end-users from residential to commercial and industrial landscapes. Current...

Continue Reading
Weyerhaeuser Set for Q2 Earnings Release July 30

Updated Category News Views 59

Building Up to the Big Reveal There's always a buzz ahead of Weyerhaeuser's earnings releases, and this one's no different. On July 30, they're set to drop the curtain on their second quarter results for 2026. Now, you'd think that's standard fare, but when you've got a giant like Weyerhaeuser (NYSE: WY) on the table, investors sit up straight. With over 10 million acres...

Continue Reading
FINBOA Honored for Innovative Compliance Solutions at PayTech Awards

Updated Category News Views 178

FINBOA Celebrated for Excellence in Payments Compliance FINBOA, a front-runner in payments dispute automation and regulatory compliance, has been recognized as a finalist for the prestigious 2025 PayTech USA Awards. This nomination is for the category of Best Regulations & Compliance in Payments Solution, demonstrating the company’s commitment to innovation and...

Continue Reading